Trial results

$ZURA — tibulizumab (ZB-106)

Zura Bio Ltd (ZURA) tibulizumab (ZB-106): trial results in hidradenitis suppurativa (HS), 2026.

Research by Catalyst Intel

The catalyst

"TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026; enrollment completed with 247 participants randomized, exceeding target"

— Zura Bio Limited, 8-K filed 2026-10-27 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

ZURA-TIBULIZUMABZ-2026

Company

Zura Bio Ltd

Kind

Trial results

Indication

hidradenitis suppurativa (HS)

Window

2026-10-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.